Artal Group S.A. Cytom X Therapeutics, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$6.47 - $7.9 $1.16 Million - $1.41 Million	-178,600 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$6.55 - $8.83 $61,570 - $83,002	-9,400 Reduced 5.0%	178,600 $1.19 Million
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $1.39 Million - $2.75 Million	188,000 New	188,000 $1.57 Million
Q2 2019 Aug 09, 2019	SELL	$9.35 - $11.41 $1.87 Million - $2.28 Million	-200,000 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$9.5 - $19.16 $475,000 - $958,000	50,000 Added 33.33%	200,000 $2.15 Million

Q4 2018 Feb 11, 2019	BUY	$12.69 - $18.61 $1.9 Million - $2.79 Million	150,000 New	150,000 $2.27 Million

43.9M

105K

4.5K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $87.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.